IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
0.1713
-0.0248 (-12.65%)
Mar 31, 2025, 2:35 PM EDT - Market open

IN8bio Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Selling, General & Admin
12.6413.5114.467.313.18
Upgrade
Research & Development
16.9616.8314.067.355.38
Upgrade
Operating Expenses
29.630.3428.5214.658.56
Upgrade
Operating Income
-29.6-30.34-28.52-14.65-8.56
Upgrade
Interest & Investment Income
0.23----
Upgrade
Other Non Operating Income (Expenses)
-0.33---
Upgrade
EBT Excluding Unusual Items
-29.37-30.01-28.52-14.65-8.56
Upgrade
Merger & Restructuring Charges
-1.07----
Upgrade
Pretax Income
-30.44-30.01-28.52-14.65-8.56
Upgrade
Net Income
-30.44-30.01-28.52-14.65-8.56
Upgrade
Preferred Dividends & Other Adjustments
----1.78
Upgrade
Net Income to Common
-30.44-30.01-28.52-14.65-10.34
Upgrade
Shares Outstanding (Basic)
543021103
Upgrade
Shares Outstanding (Diluted)
543021103
Upgrade
Shares Change (YoY)
79.30%42.43%110.32%191.59%7.24%
Upgrade
EPS (Basic)
-0.57-1.00-1.36-1.47-3.02
Upgrade
EPS (Diluted)
-0.57-1.00-1.36-1.47-3.02
Upgrade
Free Cash Flow
-24.34-23.94-27.83-13.82-7.13
Upgrade
Free Cash Flow Per Share
-0.45-0.80-1.33-1.39-2.09
Upgrade
EBITDA
-27.76-28.5-27.91-14.03-8.47
Upgrade
D&A For EBITDA
1.841.830.610.630.09
Upgrade
EBIT
-29.6-30.34-28.52-14.65-8.56
Upgrade
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q